Product Code: GVR-4-68039-957-2
Peripheral Nerve Injury Market Growth & Trends:
The global peripheral nerve injury market size is estimated to reach USD 2.58 billion by 2030, registering to grow at a CAGR of 7.80% from 2025 to 2030 according to a new report by Grand View Research, Inc. COVID-19 has had a negative impact on the market, affecting the demand and production directly, disrupting the supply chain, and increasing the financial burden on businesses. During the pandemic, a number of surgeries were regularly postponed and/or canceled to prevent the spread of COVID-19. Neurosurgical procedures decreased by 55% in the worst-hit countries, including the U.S., Russia, India, Brazil, France, the U.K., Italy, and Spain.
Furthermore, manufacturing activities, supply chain, delivery schedules, and sale of biomaterials were disrupted due to nationwide lockdowns. Moving forward, as industry players are introducing new and better technologies, the industry is expected to grow over the forecast period. For instance, in May 2022, the topline results of Clinical Study Axogen's RECON comparing conduits to Avance Nerve Graft in digital nerve injuries were disclosed by Axogen, Inc., a global pioneer in marketing and developing revolutionary surgical solutions for PNIs. The primary target for the recovery of sensory function, as defined by static two-point discrimination, was fulfilled in Phase 3 pivotal research, and the safety profile was comparable with previously reported data. This information will help the company submit a Biologics License Application (BLA) in the second half of 2023.
Peripheral Nerve Injury Market Report Highlights:
- The nerve conduit led the market and accounted for a more than 64.30% revenue share in 2024.
- The direct nerve repair segment led the market and accounted for more than 53.26% share of the global revenue in 2024.
- The upper extremities segment accounted for the largest market share in 2024 and is anticipated to grow further at the fastest CAGR from 2025 to 2030.
- North America held the largest revenue share of more than 30.43% in the market in 2024.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.3.5.1. Data for primary interviews in North America
- 1.3.5.2. Data for primary interviews in Europe
- 1.3.5.3. Data for primary interviews in Asia Pacific
- 1.3.5.4. Data for primary interviews in Latin America
- 1.3.5.5. Data for Primary interviews in MEA
- 1.4. Information or Data Analysis
- 1.4.1. Data analysis models
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.6.1. Commodity flow analysis (Model 1)
- 1.6.1.1. Approach 1: Commodity flow approach
- 1.6.2. Volume price analysis (Model 2)
- 1.6.2.1. Approach 2: Volume price analysis
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Product outlook
- 2.2.2. Surgery outlook
- 2.2.3. Application outlook
- 2.2.4. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Peripheral Nerve Injury Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Increasing government fundings and reimbursements
- 3.2.1.2. Technological advancements
- 3.2.1.3. Rising medical tourism
- 3.2.1.4. Increasing demand for 3D bioprinting approach
- 3.2.2. Market restraint analysis
- 3.2.2.1. Lack of awareness in the patients for treatment of peripheral nerve injury
- 3.2.2.2. High cost of the treatment and unavailability of trained medical personnel
- 3.3. Peripheral Nerve Injury Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
Chapter 4. Peripheral Nerve Injury Market: Product Estimates & Trend Analysis
- 4.1. Definitions and Scope
- 4.2. Product Market Share, 2024 & 2030
- 4.3. Segment Dashboard
- 4.4. Peripheral Nerve Injury Market by Product Outlook
- 4.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 4.5.1. Nerve Conduit
- 4.5.1.1. Nerve conduit market estimates and forecast 2018 to 2030 (USD Million)
- 4.5.2. Nerve Protector
- 4.5.2.1. Nerve protector market estimates and forecast 2018 to 2030 (USD Million)
- 4.5.3. Nerve Connector
- 4.5.3.1. Nerve connector market estimates and forecast 2018 to 2030 (USD Million)
- 4.5.4. Nerve Wraps
- 4.5.4.1. Nerve wraps market estimates and forecast 2018 to 2030 (USD Million)
Chapter 5. Peripheral Nerve Injury Market: Surgery Estimates & Trend Analysis
- 5.1. Definitions and Scope
- 5.2. Surgery Market Share, 2024 & 2030
- 5.3. Segment Dashboard
- 5.4. Peripheral Nerve Injury Market by Surgery Outlook
- 5.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 5.5.1. Direct Nerve Repair
- 5.5.1.1. Direct nerve repair market estimates and forecast 2018 to 2030 (USD Million)
- 5.5.2. Nerve Grafting
- 5.5.2.1. Nerve grafting market estimates and forecast 2018 to 2030 (USD Million)
- 5.5.3. Stem Cell Therapy
- 5.5.3.1. Stem cell therapy market estimates and forecast 2018 to 2030 (USD Million)
Chapter 6. Peripheral Nerve Injury Market: Application Estimates & Trend Analysis
- 6.1. Definitions and Scope
- 6.2. Application Market Share, 2024 & 2030
- 6.3. Segment Dashboard
- 6.4. Peripheral Nerve Injury Market by Application Outlook
- 6.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
- 6.5.1. Upper Extremities
- 6.5.1.1. Upper extremities market estimates and forecast 2018 to 2030 (USD Million)
- 6.5.2. Lower Extremities
- 6.5.2.1. Lower extremities market estimates and forecast 2018 to 2030 (USD Million)
Chapter 7. Peripheral Nerve Injury Market: Regional Estimates & Trend Analysis
- 7.1. Regional market share analysis, 2024 & 2030
- 7.2. Regional Market Dashboard
- 7.3. Global Regional Market Snapshot
- 7.4. Regional Market Share and Leading Players, 2024
- 7.5. Market Application, & Forecasts and Trend Analysis, 2018 to 2030:
- 7.6. North America
- 7.6.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
- 7.6.2. U.S.
- 7.6.2.1. Key country dynamics
- 7.6.2.2. Competitive scenario
- 7.6.2.3. Regulatory framework
- 7.6.2.4. Reimbursement scenario
- 7.6.2.5. U.S. market estimates and forecasts, 2018 - 2030
- 7.6.3. Canada
- 7.6.3.1. Key country dynamics
- 7.6.3.2. Competitive scenario
- 7.6.3.3. Regulatory framework
- 7.6.3.4. Reimbursement scenario
- 7.6.3.5. Canada market estimates and forecasts, 2018 - 2030
- 7.6.4. Mexico
- 7.6.4.1. Key country dynamics
- 7.6.4.2. Competitive scenario
- 7.6.4.3. Regulatory framework
- 7.6.4.4. Reimbursement scenario
- 7.6.4.5. Mexico market estimates and forecasts, 2018 - 2030
- 7.7. Europe
- 7.7.1. UK
- 7.7.1.1. Key country dynamics
- 7.7.1.2. Competitive scenario
- 7.7.1.3. Regulatory framework
- 7.7.1.4. Reimbursement scenario
- 7.7.1.5. UK market estimates and forecasts, 2018 - 2030
- 7.7.2. Germany
- 7.7.2.1. Key country dynamics
- 7.7.2.2. Competitive scenario
- 7.7.2.3. Regulatory framework
- 7.7.2.4. Reimbursement scenario
- 7.7.2.5. Germany market estimates and forecasts, 2018 - 2030
- 7.7.3. France
- 7.7.3.1. Key country dynamics
- 7.7.3.2. Competitive scenario
- 7.7.3.3. Regulatory framework
- 7.7.3.4. Reimbursement scenario
- 7.7.3.5. France market estimates and forecasts, 2018 - 2030
- 7.7.4. Italy
- 7.7.4.1. Key country dynamics
- 7.7.4.2. Competitive scenario
- 7.7.4.3. Regulatory framework
- 7.7.4.4. Reimbursement scenario
- 7.7.4.5. Italy market estimates and forecasts, 2018 - 2030
- 7.7.5. Spain
- 7.7.5.1. Key country dynamics
- 7.7.5.2. Competitive scenario
- 7.7.5.3. Regulatory framework
- 7.7.5.4. Reimbursement scenario
- 7.7.5.5. Spain market estimates and forecasts, 2018 - 2030
- 7.7.6. Denmark
- 7.7.6.1. Key country dynamics
- 7.7.6.2. Competitive scenario
- 7.7.6.3. Regulatory framework
- 7.7.6.4. Reimbursement scenario
- 7.7.6.5. Denmark market estimates and forecasts, 2018 - 2030
- 7.7.7. Sweden
- 7.7.7.1. Key country dynamics
- 7.7.7.2. Competitive scenario
- 7.7.7.3. Regulatory framework
- 7.7.7.4. Reimbursement scenario
- 7.7.7.5. Sweden market estimates and forecasts, 2018 - 2030
- 7.7.8. Norway
- 7.7.8.1. Key country dynamics
- 7.7.8.2. Competitive scenario
- 7.7.8.3. Regulatory framework
- 7.7.8.4. Reimbursement scenario
- 7.7.8.5. Norway market estimates and forecasts, 2018 - 2030
- 7.8. Asia Pacific
- 7.8.1. Japan
- 7.8.1.1. Key country dynamics
- 7.8.1.2. Competitive scenario
- 7.8.1.3. Regulatory framework
- 7.8.1.4. Reimbursement scenario
- 7.8.1.5. Japan market estimates and forecasts, 2018 - 2030
- 7.8.2. India
- 7.8.2.1. Key country dynamics
- 7.8.2.2. Competitive scenario
- 7.8.2.3. Regulatory framework
- 7.8.2.4. Reimbursement scenario
- 7.8.2.5. India market estimates and forecasts, 2018 - 2030
- 7.8.3. China
- 7.8.3.1. Key country dynamics
- 7.8.3.2. Competitive scenario
- 7.8.3.3. Regulatory framework
- 7.8.3.4. Reimbursement scenario
- 7.8.3.5. China market estimates and forecasts, 2018 - 2030
- 7.8.4. South Korea
- 7.8.4.1. Key country dynamics
- 7.8.4.2. Competitive scenario
- 7.8.4.3. Regulatory framework
- 7.8.4.4. Reimbursement scenario
- 7.8.4.5. South Korea market estimates and forecasts, 2018 - 2030
- 7.8.5. Australia
- 7.8.5.1. Key country dynamics
- 7.8.5.2. Competitive scenario
- 7.8.5.3. Regulatory framework
- 7.8.5.4. Reimbursement scenario
- 7.8.5.5. Australia market estimates and forecasts, 2018 - 2030
- 7.8.6. Thailand
- 7.8.6.1. Key country dynamics
- 7.8.6.2. Competitive scenario
- 7.8.6.3. Regulatory framework
- 7.8.6.4. Reimbursement scenario
- 7.8.6.5. Thailand market estimates and forecasts, 2018 - 2030
- 7.9. Latin America
- 7.9.1. Brazil
- 7.9.1.1. Key country dynamics
- 7.9.1.2. Competitive scenario
- 7.9.1.3. Regulatory framework
- 7.9.1.4. Reimbursement scenario
- 7.9.1.5. Brazil market estimates and forecasts, 2018 - 2030
- 7.9.2. Argentina
- 7.9.2.1. Key country dynamics
- 7.9.2.2. Competitive scenario
- 7.9.2.3. Regulatory framework
- 7.9.2.4. Reimbursement scenario
- 7.9.2.5. Argentina market estimates and forecasts, 2018 - 2030
- 7.10. MEA
- 7.10.1. South Africa
- 7.10.1.1. Key country dynamics
- 7.10.1.2. Competitive scenario
- 7.10.1.3. Regulatory framework
- 7.10.1.4. Reimbursement scenario
- 7.10.1.5. South Africa market estimates and forecasts, 2018 - 2030
- 7.10.2. Saudi Arabia
- 7.10.2.1. Key country dynamics
- 7.10.2.2. Competitive scenario
- 7.10.2.3. Regulatory framework
- 7.10.2.4. Reimbursement scenario
- 7.10.2.5. Saudi Arabia market estimates and forecasts, 2018 - 2030
- 7.10.3. UAE
- 7.10.3.1. Key country dynamics
- 7.10.3.2. Competitive scenario
- 7.10.3.3. Regulatory framework
- 7.10.3.4. Reimbursement scenario
- 7.10.3.5. UAE market estimates and forecasts, 2018 - 2030
- 7.10.4. Kuwait
- 7.10.4.1. Key country dynamics
- 7.10.4.2. Competitive scenario
- 7.10.4.3. Regulatory framework
- 7.10.4.4. Reimbursement scenario
- 7.10.4.5. Kuwait market estimates and forecasts, 2018 - 2030
Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis, By Key Market Participants
- 8.2. Company/Competition Categorization
- 8.3. Vendor Landscape
- 8.3.1. List of key distributors and channel partners
- 8.3.2. Key customers
- 8.3.3. Key company market share analysis, 2024
- 8.3.4. AxoGen, Inc.
- 8.3.4.1. Company overview
- 8.3.4.2. Financial performance
- 8.3.4.3. Product benchmarking
- 8.3.4.4. Strategic initiatives
- 8.3.5. Stryker
- 8.3.5.1. Company overview
- 8.3.5.2. Financial performance
- 8.3.5.3. Product benchmarking
- 8.3.5.4. Strategic initiatives
- 8.3.6. Baxter International, Inc.
- 8.3.6.1. Company overview
- 8.3.6.2. Financial performance
- 8.3.6.3. Product benchmarking
- 8.3.6.4. Strategic initiatives
- 8.3.7. Polyganics BV
- 8.3.7.1. Company overview
- 8.3.7.2. Financial performance
- 8.3.7.3. Product benchmarking
- 8.3.7.4. Strategic initiatives
- 8.3.8. Integra LifeSciences
- 8.3.8.1. Company overview
- 8.3.8.2. Financial performance
- 8.3.8.3. Product benchmarking
- 8.3.8.4. Strategic initiatives
- 8.3.9. Renerva, LLC.
- 8.3.9.1. Company overview
- 8.3.9.2. Financial performance
- 8.3.9.3. Product benchmarking
- 8.3.9.4. Strategic initiatives
- 8.3.10. Newrotex
- 8.3.10.1. Company overview
- 8.3.10.2. Financial performance
- 8.3.10.3. Product benchmarking
- 8.3.10.4. Strategic initiatives
- 8.3.11. Toyobo Co., Ltd.
- 8.3.11.1. Company overview
- 8.3.11.2. Financial performance
- 8.3.11.3. Product benchmarking
- 8.3.11.4. Strategic initiatives
- 8.3.12. Orthocell Ltd
- 8.3.12.1. Company overview
- 8.3.12.2. Financial performance
- 8.3.12.3. Product benchmarking
- 8.3.12.4. Strategic initiatives